Guardant Health, Inc.
Guardant Health, Inc. (Nasdaq: GH) is a precision oncology company that develops blood- and tissue-based tests, real-world data resources and analytical tools for cancer care and research. Its tests support therapy selection for advanced cancers, detection of residual or recurring disease, therapy-response monitoring… From the company’s description.
In fiscal 2025, Guardant Health, Inc. reported revenue of $982.02M, up 32.9% from fiscal 2024, and a net loss of $416.28M. Its operating margin was −44.5%, and operations used $184.76M in cash. Over the twelve months to Jun 30, 2026, revenue was $1.18B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Guardant Health, Inc. does
In the company’s own words
Guardant Health, Inc. (Nasdaq: GH) is a precision oncology company that develops blood- and tissue-based tests, real-world data resources and analytical tools for cancer care and research. Its tests support therapy selection for advanced cancers, detection of residual or recurring disease, therapy-response monitoring and cancer screening. Products include Guardant360 tests for molecular profiling, Guardant Reveal for disease monitoring, and Shield for colorectal cancer screening in adults aged 45 and older at average risk. The company also serves biopharmaceutical customers with tests and data tools for clinical research, biomarker discovery, drug development and clinical-study enrollment, including GuardantINFINITY and GuardantOMNI tests and the GuardantINFORM platform. Its products use the Smart Platform, which combines genomic, epigenomic and RNA-based data with proprietary chemistry and analytical tools. Guardant Health sells to clinical customers, including oncologists, cancer centers and primary care providers, and works with biopharmaceutical companies in the United States and internationally. It performs clinical and research testing at laboratories in California and New York.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 1576280
- SIC
- 8071
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Guardant Health, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Guardant Health, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Guardant Health, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Guardant Health, Inc.’s bonds, as funds hold them
Funds report holding 3 issues of Guardant Health, Inc.’s debt, $263.19M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.75%, maturing 2027 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Guardant Health, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Guardant Health, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Guardant Health, Inc.'s last four quarterly filings that the numbers alone won't show?”